about
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases suc...
Read More
11.33
-0.08
(-0.70%)
435.8K
XNAS Volume
XNAS 14 May, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for Climb Bio Inc is on 19 May 2026 for the purpose of H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
See details
Not Eligible
Expensive Valuation
Technically Bullish
Climb Bio Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..